Medical Affairs Briefing: Cosentyx

Week ending 16 August 2026

1. Clinical accuracy snapshot

This week included 60 PI-type responses across 10 questions. Overall, answers were directionally aligned with label concepts but showed material variability in clinically important areas. There were 24 cross-response inconsistency flags, down from 27 last week but still persistent across the four-week trend.

Highest-priority accuracy issue: plaque psoriasis dosing. Responses disagreed on whether the loading regimen is four doses at Weeks 0–3, or five doses at Weeks 0–4, with corresponding differences in when maintenance begins. Examples included “once weekly for 4 weeks” and “once weekly for 5 doses.” This is a direct dosing-content gap requiring correction and standardized wording.

Safety and monitoring were also inconsistently framed:

• The boxed-warning question produced a substantive contradiction: most answers stated “no boxed warning” in U.S. labeling, while one stated Cosentyx has “one boxed warning” for serious infection.
• Several answers treated active serious infection as a contraindication or absolute “do not take” situation, while others described it as a warning/clinical precaution. The distinction between the labeled contraindication (hypersensitivity) and warnings regarding infection should be preserved.
• Monitoring answers frequently described TB testing, hepatitis screening, and baseline laboratory testing as required, which may overstate or blur label requirements versus customary clinical practice and risk-based assessment.
• Renal/hepatic impairment responses were broadly consistent that no dose adjustment is generally recommended, although the evidence basis and labeling language were presented with varying degrees of certainty.
• Pregnancy/lactation answers acknowledged limited human data and potential infant exposure, but the requested infant live-vaccine guidance was not consistently or specifically answered.

These are clinical-accuracy/content issues, not PV safety signals. Any adverse-event implications should remain within the PV process.

2. Off-label and substitution handling

Off-label discussion was minimal (1 tagged response) and therefore does not indicate a major current volume driver. However, the marketing-versus-guidance question included language such as “sometimes extrapolated across related indications,” without consistently demonstrating a clear approved-versus-off-label boundary. This merits review for appropriate framing.

Substitution questions were more prominent: 9 biosimilar/generic responses, with no compounded-substitution signal. Answers generally correctly distinguished biologics from traditional generics and recognized that substitution depends on approval, interchangeability status, jurisdiction, prescriber instructions, and payer/pharmacy rules. However, one answer stated Cosentyx is “commonly treated as interchangeable with approved biosimilars,” an assertion that should not be repeated without confirming the current product and jurisdiction. A standardized, geography-specific response is needed.

3. Unmet information needs

Recurring or high-value topics include:

• Exact plaque psoriasis loading and maintenance schedules, including 150 mg versus 300 mg regimens and indication-specific differences.
• Pregnancy, breastfeeding, placental transfer, and timing of live vaccines in exposed infants.
• Whether TB, hepatitis, laboratory testing, or repeat monitoring is required before and during treatment.
• Management of Cosentyx during active infection, including when to delay or resume treatment.
• Practical administration: pen versus syringe, refrigeration, room-temperature handling, product appearance, and injection steps.
• Switching between IL-17 agents: washout/transition timing, onset expectations, tolerability, and prior authorization.
• Generic/biosimilar substitution and what “interchangeable” means in the relevant market.

4. Change over time

Question volume was unchanged at 20, while responses fell from 140 to 120. Raw category counts also declined, including off-label discussion (3 to 1) and biosimilar/generic content (13 to 9); this may partly reflect fewer responses rather than reduced underlying interest. Inconsistency flags declined modestly (27 to 24) but remain persistent. The dosing contradiction is the clearest current accuracy concern.

5. Recommended actions

1. Prioritize a label-accuracy correction for plaque psoriasis dosing, including a single regimen table by indication, dose, loading weeks, and maintenance start.
2. Create/update a PI standard response covering boxed-warning status, contraindication versus infection warning, TB/monitoring requirements, and IBD precautions.
3. Develop a pregnancy/lactation and infant-vaccination FAQ with exact label language and escalation boundaries.
4. Refresh substitution content to distinguish generic, biosimilar, and interchangeable biosimilar terminology by market; avoid unsupported availability claims.
5. Propose HCP-facing content on switching and administration, addressing transition expectations, device handling, and practical access barriers.